Neurocrine Biosciences (NBIX) 10-K11 Feb 142013 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2013	Jan. 24, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'NBIX	'	'
Entity Registrant Name	'NEUROCRINE BIOSCIENCES INC	'	'
Entity Central Index Key	'0000914475	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	67,793,709	'
Entity Public Float	'	'	$646,990,582

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$44,789	$63,754
Short-term investments, available-for-sale	100,950	109,259
Receivables under collaborative agreements	23	14,089
Other current assets	2,700	2,162
Total current assets	148,462	189,264
Property and equipment, net	1,771	1,900
Long-term investments	'	480
Restricted cash	4,443	4,335
Total assets	154,676	195,979
Current liabilities:	'	'
Accounts payable	101	911
Accrued liabilities	7,955	8,094
Current portion of deferred revenues	'	2,919
Current portion of cease-use liability	416	589
Current portion of deferred gain on sale of real estate	3,227	3,133
Total current liabilities	11,699	15,646
Deferred gain on sale of real estate	17,645	20,872
Deferred rent	1,982	1,840
Cease-use liability	2,680	3,097
Other liabilities	260	152
Total liabilities	34,266	41,607
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value; 110,000,000 shares authorized; issued and outstanding shares were 67,351,195 and 66,446,888 at December 31, 2013 and 2012, respectively	67	66
Additional paid-in capital	886,101	873,981
Accumulated other comprehensive gain (loss)	5	-2
Accumulated deficit	-765,763	-719,673
Total stockholders' equity	120,410	154,372
Total liabilities and stockholders' equity	$154,676	$195,979

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	110,000,000	110,000,000
Common stock, shares issued	67,351,195	66,446,888
Common stock, shares outstanding	67,351,195	66,446,888

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive (Loss) Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Sponsored research and development	'	$18,897	$10,462
Milestones and license fees	2,919	34,243	66,951
Total revenues	2,919	53,140	77,413
Operating expenses:	'	'	'
Research and development	39,248	37,163	30,951
General and administrative	13,349	13,437	12,458
Cease-use expense	'	1,092	82
Total operating expenses	52,597	51,692	43,491
(Loss) income from operations	-49,678	1,448	33,922
Other income:	'	'	'
Gain on sale/disposal of assets	37	32	242
Deferred gain on real estate	3,133	3,042	2,953
Investment income, net	402	489	418
Other income, net	16	14	36
Total other income	3,588	3,577	3,649
Net (loss) income	-46,090	5,025	37,571
Net (loss) income per common share:	'	'	'
Basic	($0.69)	$0.08	$0.68
Diluted	($0.69)	$0.08	$0.67
Shares used in the calculation of net (loss) income per common share:	'	'	'
Basic	66,989	65,619	55,176
Diluted	66,989	66,946	56,347
Other comprehensive (loss) income:	'	'	'
Net (loss) income	-46,090	5,025	37,571
Net unrealized gains (losses) on available-for-sale securities	7	85	-39
Comprehensive (loss) income	($46,083)	$5,110	$37,532

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders Equity (USD $)	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
In Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance at Dec. 31, 2010	$19,345	$55	$781,607	($48)	($762,269)
Beginning balance (in shares) at Dec. 31, 2010	'	54,882	'	'	'
Net income (loss)	37,571	0	0	0	37,571
Unrealized gains (losses) on investments	-39	0	0	-39	0
Share-based compensation	2,918	0	2,918	0	0
Issuance of common stock for restricted share units vested	0	0	0	0	0
Issuance of common stock for restricted share units vested (in shares)	'	287	'	'	'
Issuance of common stock for option exercises	286	0	286	0	0
Issuance of common stock for option exercises (in shares)	94	94	'	'	'
Ending balance at Dec. 31, 2011	60,081	55	784,811	-87	-724,698
Ending balance (in shares) at Dec. 31, 2011	'	55,263	'	'	'
Net income (loss)	5,025	0	0	0	5,025
Unrealized gains (losses) on investments	85	0	0	85	0
Share-based compensation	5,479	0	5,479	0	0
Issuance of common stock for restricted share units vested	0	0	0	0	0
Issuance of common stock for restricted share units vested (in shares)	'	50	'	'	'
Issuance of common stock for option exercises	731	0	731	0	0
Issuance of common stock for option exercises (in shares)	209	209	'	'	'
Issuance of common stock, net of offering costs	82,971	11	82,960	0	0
Issuance of common stock, net of offering costs (in shares)	'	10,925	'	'	'
Ending balance at Dec. 31, 2012	154,372	66	873,981	-2	-719,673
Ending balance (in shares) at Dec. 31, 2012	'	66,447	'	'	'
Net income (loss)	-46,090	0	0	0	-46,090
Unrealized gains (losses) on investments	7	0	0	7	0
Share-based compensation	6,819	0	6,819	0	0
Issuance of common stock for option exercises	5,302	1	5,301	0	0
Issuance of common stock for option exercises (in shares)	904	904	'	'	'
Ending balance at Dec. 31, 2013	$120,410	$67	$886,101	$5	($765,763)
Ending balance (in shares) at Dec. 31, 2013	'	67,351	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOW FROM OPERATING ACTIVITIES	'	'	'
Net (loss) income	($46,090)	$5,025	$37,571
Adjustments to reconcile net (loss) income to net cash used in operating activities:	'	'	'
Depreciation and amortization	671	657	694
Gain on sale of assets	-3,170	-3,074	-3,195
Cease-use expense	'	1,092	82
Deferred revenues	-2,919	-34,242	-37,027
Deferred rent	142	305	434
Amortization of premiums on investments	2,843	3,135	2,341
Non-cash share-based compensation expense	6,819	5,479	2,918
Change in operating assets and liabilities:	'	'	'
Accounts receivable and other assets	13,528	-12,878	2,813
Cease-use liability	-590	-263	-7,502
Other liabilities	108	27	24
Accounts payable and accrued liabilities	-949	-557	149
Net cash used in operating activities	-29,607	-35,294	-698
CASH FLOW FROM INVESTING ACTIVITIES	'	'	'
Purchases of investments	-145,328	-166,313	-139,099
Sales/maturities of investments	151,281	132,520	134,276
Deposits and restricted cash	-108	-29	1,796
Proceeds from sales of property and equipment	40	32	245
Purchases of property and equipment	-545	-971	-750
Net cash provided by (used in) investing activities	5,340	-34,761	-3,532
CASH FLOW FROM FINANCING ACTIVITIES	'	'	'
Issuance of common stock	5,302	83,702	286
Net cash provided by financing activities	5,302	83,702	286
Net change in cash and cash equivalents	-18,965	13,647	-3,944
Cash and cash equivalents at beginning of the year	63,754	50,107	54,051
Cash and cash equivalents at end of the year	44,789	63,754	50,107
SUPPLEMENTAL DISCLOSURES	'	'	'
Taxes paid	$0	$0	$0

ORGANIZATION_AND_SUMMARY_OF_SI

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business Activities. Neurocrine Biosciences, Inc. (the Company or Neurocrine) was incorporated in California in 1992 and reincorporated in Delaware in 1996. The Company discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and a wholly owned vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of the Company and is inactive.

Principles of Consolidation. The consolidated financial statements include the accounts of Neurocrine as well as its wholly owned subsidiary. The Company does not have any significant interests in any variable interest entities. All intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

Cash Equivalents. The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be cash equivalents.

Short-Term Investments Available-for-Sale. Certain short-term investments are classified as available-for-sale and, in accordance with authoritative guidance, are carried at fair value, with the unrealized gains and losses reported in other comprehensive (loss) income. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.

Concentration of Credit Risk. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that maintain safety and liquidity.

Collaboration Agreements. During the years ended December 31, 2013, 2012, and 2011, collaborative research and development agreements accounted for all of the Company’s revenue.

Property and Equipment. Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of three to seven years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term.

Industry Segment and Geographic Information. The Company operates in a single industry segment – the discovery and development of therapeutics for the treatment of neurological and endocrine-related diseases and disorders. The Company had no foreign based operations during any of the years presented.

Impairment of Long-Lived Assets. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the carrying amount is not recoverable, the Company measures the amount of any impairment by comparing the carrying value of the asset to the present value of the expected future cash flows associated with the use of the asset.

Fair Value of Financial Instruments. Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments.

Research and Development Expenses. Research and development (R&D) expenses consists primarily of salaries, payroll taxes, employee benefits, and share-based compensation charges, for those individuals involved in ongoing R&D efforts; as well as scientific contractor fees, preclinical and clinical trial costs, R&D facilities costs, laboratory supply costs, and depreciation of scientific equipment. All such costs are charged to R&D expense as incurred. These expenses result from the Company’s independent R&D efforts as well as efforts associated with collaborations and in-licensing arrangements. In addition, the Company funds R&D at other companies and research institutions under agreements, which are generally cancelable. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.

Share-Based Compensation. The Company estimates the fair value of stock options using the Black-Scholes option pricing model on the date of grant. Restricted stock units are valued based on the closing price of the Company’s common stock on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally three to four years; however, certain provisions in the Company’s equity compensation plans provide for shorter vesting periods under certain circumstances.

Investment Income, net. Investment income, net is comprised of interest and dividends earned on cash, cash equivalents and investments as well as gains and losses realized from activity in the Company’s investment portfolio. The following table presents certain information related to the components of investment income (in thousands):

Years Ended December 31,

2013

2012

2011

Interest income

400

489

435

Realized gains/(losses), net

—

(17

)

Total

402

489

418

Net (Loss) Income Per Share. The Company computes basic net (loss) income per share using the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under the Company’s stock option agreements. Common share equivalents are excluded from the diluted net loss per share calculation because of their anti-dilutive effect.

Due to the net loss position in 2013, approximately 2.1 million of common share equivalents were excluded from the diluted common shares outstanding. At December 31, 2012 and 2011, the Company had approximately 1.3 million and 1.2 million, respectively, of additional common share equivalents outstanding that were included in the diluted income per share calculation. For the years ended December 31, 2013, 2012 and 2011, there were employee stock options and restricted stock units outstanding, calculated on a weighted average basis, to purchase 0.3 million, 2.2 million and 1.3 million shares of our common stock with an exercise price greater than the average market price of the underlying common shares.

Impact of Recently Issued Accounting Standards. In December 2011, the Financial Accounting Standards Board (FASB) issued accounting guidance requiring an entity to disclose information about offsetting arrangements and the impact of these arrangements on the Company’s financial position. This guidance is effective for interim and annual periods beginning on or after January 1, 2013. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.

In February 2013, the FASB amended the disclosure requirements regarding the reporting of amounts reclassified out of accumulated other comprehensive income. The amendment does not change the current requirement for reporting net income or other comprehensive income, but requires additional disclosures about significant amounts reclassified out of accumulated other comprehensive income including the effect of the reclassification on the related net income line items. This amendment was adopted prospectively by the Company effective January 1, 2013 and did not have a significant impact on the Company’s consolidated financial statements as the requirements are disclosure only in nature.

In July 2013, the FASB issued guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. The Company intends to adopt this guidance during the first quarter of 2014, and does not believe the adoption of this standard will have a material impact on the Company’s consolidated financial statements.

REVENUE_RECOGNITION_AND_SIGNIF

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	12 Months Ended
	Dec. 31, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	'
	NOTE 2. REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS
	Revenue Recognition Policy. Revenues under collaborative agreements and grants are recognized as research costs are incurred over the period specified in the related agreement or as the services are performed. These agreements are on a best-efforts basis, do not require scientific achievement as a performance obligation and provide for payment to be made when costs are incurred or the services are performed. All fees are nonrefundable to the collaborators. Prior to the revised multiple element guidance adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Estimating the duration of the development period includes continual assessment of development stages and regulatory requirements. If and when the Company enters into a new collaboration agreement or materially modifies an existing collaboration agreement, the Company will be required to apply the new multiple element guidance. Milestone payments are recognized as revenue upon achievement of pre-defined scientific events, which require substantive effort, and for which achievement of the milestone was not readily assured at the inception of the agreement.
	AbbVie Inc. (AbbVie). In June 2010, the Company announced an exclusive worldwide collaboration with AbbVie, to develop and commercialize elagolix and all next-generation GnRH antagonists (collectively, GnRH Compounds) for women’s and men’s health. AbbVie made an upfront payment of $75 million and has agreed to make additional development and regulatory event based payments of up to $480 million and up to an additional $50 million in commercial event based payments. The Company has assessed event based payments under the revised authoritative guidance for research and development milestones and determined that event based payments prior to commencement of a Phase III clinical study, as defined in the agreement, meet the definition of a milestone in accordance with authoritative guidance as (1) they are events that can only be achieved in part on the Company’s past performance, (2) there is substantive uncertainty at the date the arrangement was entered into that the event will be achieved and (3) they result in additional payments being due to the Company. Development and regulatory event based payments subsequent to the commencement of a Phase III clinical study, however, currently do not meet these criteria as their achievement is based on the performance of AbbVie. During the year ended December 31, 2011, the Company recognized $30.0 million in milestone revenue under the AbbVie collaboration, $10.0 million of which was related to advancing elagolix into Phase II clinical trials for uterine fibroids and $20.0 million of which was related to the outcome of an elagolix pre- Phase III meeting with the U.S. Food and Drug Administration (FDA) for endometriosis. As of December 31, 2013, there are no further event based payments that meet the definition of a milestone in accordance with authoritative guidance.
	Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing and commercialization costs. The Company received funding for certain internal collaboration expenses which included reimbursement from AbbVie for internal and external expenses related to the GnRH Compounds through the end of 2012. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. Under the terms of the Company’s agreement with AbbVie, the collaboration effort between the parties to advance GnRH Compounds towards commercialization was governed by a joint development committee with representatives from both the Company and AbbVie. AbbVie may terminate the collaboration at its discretion upon 180 days’ written notice to the Company. In such event, the Company would be entitled to specified payments for ongoing clinical development and related activities and all GnRH Compound product rights would revert to the Company. The Company’s participation in the joint development committee was determined to be a substantive deliverable under the contract, and therefore, the upfront payment was deferred and recognized over the term of the joint development committee, which was completed, as scheduled, in December 2012. During 2012, the Company recorded $13.1 million in revenue related to completion of the collaborative development period which is included in sponsored research and development revenue.
	There was no revenue recognized in 2013 related to this collaboration. During the years ended December 31, 2012 and 2011, revenues recognized under the collaboration agreement with AbbVie were as follows (in millions):


		Year Ended
		December 31,
		2012		2011
	Milestones and amortization of up-front license fees	$	29.1	$	59
	Sponsored research and development		17.8		9.1

	Revenues recognized under the AbbVie collaboration agreement	$	46.9	$	68.1

	Boehringer Ingelheim International GmbH (Boehringer Ingelheim). In June 2010, the Company announced a worldwide collaboration with Boehringer Ingelheim to research, develop and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. Under the terms of the Company’s agreement with Boehringer Ingelheim, the Company and Boehringer Ingelheim worked jointly, during a two year collaborative research period which ended in June 2012, to identify and advance GPR119 agonist candidates into preclinical development. Following the collaborative research period, Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products, if any. The Company received a $10 million upfront payment, and received research funding to support discovery efforts. Boehringer Ingelheim agreed to make payments of up to approximately $3 million in additional preclinical milestone payments and payments of up to approximately $223 million in clinical development and commercial event based payments. The Company has assessed milestones under the revised authoritative guidance for research and development milestones and determined that the preclinical milestone payments, as defined in the agreement, meet the definition of a milestone as (1) they are events that can only be achieved in part on the Company’s performance or upon the occurrence of a specific outcome resulting from the Company’s performance, (2) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (3) they result in additional payments being due to the Company. Clinical development and commercial milestone payments, however, currently do not meet these criteria as their achievement is solely based on the performance of Boehringer Ingelheim. No milestone payments were recognized during the periods presented. The Company will be entitled to a percentage of any future worldwide sales of GPR119 agonists. Under the terms of the agreement, the collaboration effort between the parties to identify and advance GPR119 agonist candidates into preclinical development was initially governed by a steering committee with representatives from both the Company and Boehringer Ingelheim; provided, however, that final decision making authority rested with Boehringer Ingelheim. The Company’s participation in the steering committee was determined to be a substantive deliverable under the contract, and therefore, the upfront payment was deferred and recognized over the two-year term of the steering committee which was completed, as scheduled, in June 2012. Boehringer Ingelheim may terminate the agreement at its discretion upon prior written notice to the Company. In such event, the Company may be entitled to specified payments and product rights would revert to the Company.
	There was no revenue recognized in 2013 related to this collaboration. During the years ended December 31, 2012 and 2011, revenues recognized under the collaboration agreement with Boehringer Ingelheim were as follows (in millions):


		Year Ended
		December 31,
		2012		2011
	Amortization of up-front license fees	$	2.2	$	5
	Sponsored research and development		1		1.3

	Revenues recognized under the Boehringer Ingelheim collaboration agreement	$	3.2	$	6.3

	Dainippon Sumitomo Pharma Co., Ltd. (DSP). In October 2007, the Company entered into an exclusive license agreement with DSP, under which the Company licensed rights to indiplon to DSP and agreed to collaborate with DSP on the development and commercialization of indiplon in Japan. Pursuant to the license agreement, among other things, the Company received an up-front license fee of $20 million. The Company is also eligible to receive additional event based payments upon specified future events related to the development and commercialization of indiplon in Japan. Should all event based payments be achieved, the Company may be entitled to payments totaling an additional $115 million. Event based payments under the DSP agreement do not meet the criteria of a milestone in accordance with the authoritative guidance as they are based on the performance of DSP. Additionally, the Company is entitled to royalties from DSP on future sales of indiplon in Japan. For each of the years ending December 31, 2013, 2012 and 2011, the Company amortized annually into revenue $2.9 million of the upfront license fee under the DSP agreement.
	GlaxoSmithKline (GSK). In July 2001, the Company announced a worldwide collaboration with GSK to develop and commercialize CRF antagonists for psychiatric, neurological and gastrointestinal diseases. Under the terms of this agreement, the Company and GSK conducted a collaborative research program and collaborated in the development of Neurocrine’s current lead CRF compounds, as well as novel back-up candidates and second generation compounds identified through the collaborative research. The Company recognized $0.1 million in revenue under the GSK agreement in each of the years ended December 31, 2012 and 2011.
	In September 2012, the Company and GSK entered into a Termination Agreement, pursuant to which the parties mutually agreed to terminate the collaboration agreement. Pursuant to the terms of the Termination Agreement, GSK’s license to the Company’s CRF assets terminated, reverting all rights to the Company and GSK assigned to the Company all patent rights created from the sponsored research portion of the collaboration agreement, including all related regulatory filings and approvals. GSK also assigned to the Company all other patents, regulator and technology assets that were owned or controlled by GSK and its affiliates necessary for the development and commercialization of CRF antagonist compounds.

INVESTMENTS

INVESTMENTS	12 Months Ended
INVESTMENTS	Dec. 31, 2013
Investments Schedule [Abstract]	'
INVESTMENTS	'
	NOTE 3. INVESTMENTS
	Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.

	Investments at December 31, 2013 and 2012 consisted of the following (in thousands):


			Years Ended
			December 31,
			2013			2012
	Certificates of deposit		$	11,012		$	12,434
	Commercial paper			4,997			19,695
	Corporate debt securities			77,441			77,610
	Securities of government-sponsored entities			7,500			—

	Total investments		$	100,950		$	109,739

	The following is a summary of investments classified as available-for-sale securities (in thousands):


			Contractual			Amortized			Gross			Gross				Aggregate
			Maturity			Cost			Unrealized			Unrealized				Estimated
			(in years)						Gains(1)			Losses(1)				Fair
																Value
	December 31, 2013:
	Classified as current assets:
	Certificates of deposit			Less than 1		$	11,018		$	1		$	(7	)		$	11,012
	Commercial paper			Less than 1			4,997			—			—				4,997
	Corporate debt securities			Less than 1			77,430			19			(8	)			77,441
	Securities of government-sponsored entities			Less than 1			7,500			—			—				7,500

	Total short-term available-for-sale securities					$	100,945		$	20		$	(15	)		$	100,950

	December 31, 2012:
	Classified as current assets:
	Certificates of deposit			Less than 1		$	11,960		$	—		$	(6	)		$	11,954
	Commercial paper			Less than 1			19,713			—			(18	)			19,695
	Corporate debt securities			Less than 1			77,588			33			(11	)			77,610

	Total short-term available-for-sale securities					$	109,261		$	33		$	(35	)		$	109,259

	Classified as non-current assets:
	Certificates of deposit			1 to 2		$	480		$	—		$	—			$	480

	Total long-term available-for-sale securities					$	480		$	—		$	—			$	480


	-1	Unrealized gains and losses are included in other comprehensive income.
	The following table presents certain information related to sales and maturities of available-for-sale investments (in thousands):


			Year Ended December 31,
			2013			2012			2011
	Proceeds from sales/maturities of available-for-sale securities		$	151,283		$	132,520		$	134,259
	Gross realized gains on sales of available-for-sale securities			2			—			—
	Gross realized losses on sales of available-for-sale securities			—			—			17
	Gains reclassified out of accumulated other comprehensive (loss) income into earnings			—			—			—

	The following table presents information about available-for-sale investments in an unrealized loss position (in thousands):


			Less Than 12 Months						12 Months or Greater							Total
			Estimated			Unrealized			Estimated			Unrealized				Estimated			Unrealized
			Fair Value			Losses			Fair Value			Losses				Fair Value			Losses
December 31, 2013:
Certificates of deposit		$	9,802		$	(7	)	$	—		$	—			$	9,802		$	(7	)
Corporate debt securities			29,919			(8	)		—			—				29,919			(8	)

Total		$	39,721		$	(15	)	$	—		$	—			$	39,721		$	(15	)

December 31, 2012:
Certificates of deposit		$	10,273		$	(6	)	$	—		$	—			$	10,273		$	(6	)
Commercial paper			19,695			(18	)		—			—				19,695			(18	)
Corporate debt securities			37,524			(11	)		—			—				37,524			(11	)

Total		$	67,492		$	(35	)	$	—		$	—			$	67,492		$	(35	)

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
FAIR VALUE MEASUREMENTS	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	NOTE 4. FAIR VALUE MEASUREMENTS
	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:


	Level 1:	Observable inputs such as quoted prices in active markets;

	Level 2:	Inputs include quoted prices for similar instruments in active markets and/or quoted prices for identical or similar instruments in markets that are not active near the measurement date; and

	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The Company classifies its cash equivalents and available for sale investments within Level 1 or Level 2. The fair value of the Company’s high quality investment grade corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not reclassify any investments between levels in the fair value hierarchy during the years ended December 31, 2013 and 2012.

	The Company’s assets which are measured at fair value on a recurring basis as of December 31, 2013 and 2012 were determined using the inputs described above (in millions):


					Fair Value Measurements Using
		Carrying			Quoted Prices in			Significant Other			Significant
		Value			Active Markets for			Observable			Unobservable Inputs
					Identical Assets			Inputs			(Level 3)
					(Level 1)			(Level 2)
	December 31, 2013:
	Classified as current assets:
	Cash and money market funds	$	34.9		$	34.9		$	—		$	—
	Certificates of deposit		11			11			—			—
	Commercial paper		5			—			5			—
	Securities of government-sponsored entities		7.5			—			7.5			—
	Corporate debt securities		87.4			—			87.4			—

	Subtotal		145.8			45.9			99.9			—
	Classified as long-term assets:
	Certificates of deposit		4.4			4.4			—			—

	Total		150.2			50.3			99.9			—
	Less cash, cash equivalents and restricted cash		(49.2	)		(39.3	)		(9.9	)		—

	Total investments	$	101		$	11		$	90		$	—

	December 31, 2012:
	Classified as current assets:
	Cash and money market funds	$	53.2		$	53.2		$	—		$	—
	Certificates of deposit		11.9			11.9			—			—
	Commercial paper		25.7			—			25.7			—
	Corporate debt securities		82.2			—			82.2			—

	Subtotal		173			65.1			107.9			—
	Classified as long-term assets:
	Certificates of deposit		4.8			4.8			—			—

	Total		177.8			69.9			107.9			—
	Less cash, cash equivalents and restricted cash		(68.1	)		(57.5	)		(10.6	)		—

	Total investments	$	109.7		$	12.4		$	97.3		$	—

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
PROPERTY AND EQUIPMENT	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	NOTE 5. PROPERTY AND EQUIPMENT
	Property and equipment, net, at December 31, 2013 and 2012 consisted of the following (in thousands):


		2013			2012
	Tenant improvements		1,195			1,195
	Furniture and fixtures		819			819
	Equipment		28,089			34,209

			30,103			36,223
	Less accumulated depreciation		(28,332	)		(34,323	)

	Property and equipment, net	$	1,771		$	1,900

	For each of the years ended December 31, 2013, 2012 and 2011, depreciation expense was $0.7 million. During 2013, 2012 and 2011, the Company recognized a gain of approximately $37,000, $32,000 and $242,000, respectively, related to disposal of capital equipment.

ACCRUED_LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
ACCRUED LIABILITIES	Dec. 31, 2013
Payables And Accruals [Abstract]	'
ACCRUED LIABILITIES	'
	NOTE 6. ACCRUED LIABILITIES
	Accrued liabilities at December 31, 2013 and 2012 consisted of the following (in thousands):


		2013		2012
	Accrued employee related costs	$	3,403	$	3,811
	Accrued development costs		1,387		1,231
	Other accrued liabilities		3,165		3,052

		$	7,955	$	8,094

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 7. COMMITMENTS AND CONTINGENCIES
	Real Estate. In December 2007, the Company closed the sale of its facility and associated real property for a purchase price of $109 million. Concurrent with the sale, the Company retired the entire $47.7 million in mortgage debt previously outstanding with respect to the facility and associated real property, and received cash of $61.0 million net of transaction costs and debt retirement.
	Upon the closing of the sale of the facility and associated real property, the Company entered into a lease agreement (Lease) with DMH Campus Investors, LLC (DMH) whereby it leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building. The ultimate result of this real estate sale was a net gain of $39.1 million which was deferred in accordance with authoritative guidance. For the years ended December 31, 2013, 2012 and 2011, the Company recognized $3.1 million, $3.0 million and $3.0 million, respectively, of the deferred gain and will recognize the remaining $20.9 million of the deferred gain over the initial Lease term which will expire at the end of 2019.
	Under the terms of the Lease and the Amendments, the Company pays base annual rent (subject to an annual fixed percentage increase), plus a 3.5% annual management fee, property taxes and other normal and necessary expenses associated with the Lease such as utilities, repairs and maintenance. In lieu of a cash security deposit under the Lease, Wells Fargo Bank, N.A. issued on the Company’s behalf a letter of credit in the amount of $4.2 million, which is secured by a deposit of equal amount with the same bank. The Company also has the right to extend the Lease for two consecutive ten-year terms.
	In December 2010, the Company entered into a sublease agreement (Sublease) for approximately 16,000 square feet of the Rear Building. The Sublease is expected to result in approximately $0.6 million of rental income per year over the three year term of the Sublease and is recorded as an offset to rent expense. The Sublease provides an option to extend for two one-year renewal periods. The income generated under the Sublease is lower than the Company’s financial obligation under the Lease for the Rear Building with DMH, as determined on a per square foot basis. Consequently, at December 31, 2010 the Company was required to record a cease-use liability for the net present value estimated difference between the expected income to be generated under the Sublease and future subleases and the Lease obligation over the remaining term of the Lease for the space that is occupied by the subtenant. This transaction resulted in $2.5 million of gross cease-use expense, and a reversal of $173,000 in associated deferred rent, being recorded in December 2010. In August 2012, the Company extended the terms of the Sublease and increased the leased square footage to approximately 17,000 square feet. This transaction resulted in approximately $150,000 of gross cease-use expense, and a reversal of $15,000 in associated deferred rent, being recorded in September 2012.
	In September 2011, the Company entered into a second sublease agreement (Second Sublease) for approximately 3,300 square feet of space in the Rear Building. The Second Sublease is expected to result in approximately $0.1 million in rental income per year over the three year term and is recorded as an offset to rent expense. The Second Sublease provides an option to extend for a one-year renewal period which was exercised in 2013. Similar to the Sublease, the Second Sublease resulted in $0.3 million of gross cease-use expense, and a reversal of $47,000 in associated deferred rent, being recorded in September 2011.
	In November 2012, the Company entered into a third sublease agreement (Third Sublease) for approximately 14,000 square feet of space in the Rear Building. The Third Sublease is expected to result in approximately $0.5 million in rental income per year over the three and a half year term and is recorded as an offset to rent expense. The Third Sublease provides the subtenant with an option to extend the term for two one-year renewal periods. Similar to the previous subleases, the Third Sublease resulted in $1.2 million of gross cease-use expense, and a reversal of $250,000 in associated deferred rent, being recorded in December 2012.
	The following table sets forth changes to the accrued cease-use liability during 2013 and 2012 (in thousands):


			Years Ended
			December 31,
			2013			2012
	Beginning balance		$	3,686		$	2,592
	Impact of Sublease cease-use charges(1)			—			1,360
	Change in estimate			—			(3	)
	Payments			(590	)		(263	)

	Ending balance		$	3,096		$	3,686


	-1	Total sublease cease-use expense was offset by a related adjustment to deferred rent of approximately $265,000 during 2012.
	Rent Expense. Rent expense was $5.9 million, $5.9 million and $6.2 million for the years ended December 31, 2013, 2012 and 2011, respectively. For financial reporting purposes, the Company recognizes rent expense on a straight-line basis over the term of the lease. Accordingly, rent expense recognized in excess of rent paid is reflected as a liability in the accompanying consolidated balance sheets.
	Lease Commitments. The Company leases its office and research laboratories under an operating lease with an initial term of twelve years, expiring at the end of 2019. Additionally, the Company’s facility lease agreement calls for it to maintain $50 million in cash and investments at all times, or to increase the security deposit by $5 million.
	As of December 31, 2013, the total estimated future annual minimum lease payments under the Company’s non-cancelable building lease for the years ending after December 31, 2013 are as follows (in thousands):


			Payment Amount
	2014		$	7,169
	2015			7,385
	2016			7,606
	2017			7,834
	2018			8,070
	Thereafter			8,311

	Total future minimum lease payments		$	46,375

	Product Liability. The Company’s business exposes it to liability risks from its potential drug products. A successful product liability claim or series of claims brought against the Company could result in payment of significant amounts of money and divert management’s attention from running the business. The Company may not be able to maintain insurance on acceptable terms, or the insurance may not provide adequate protection in the case of a product liability claim. To the extent that product liability insurance, if available, does not cover potential claims, the Company would be required to self-insure the risks associated with such claims. The Company believes that it carries reasonably adequate insurance for product liability claims.
	Licensing and Research Agreements. The Company has entered into inlicensing agreements with various universities and research organizations, which are generally cancelable at the option of the Company with terms ranging from 0-180 days written notice. Under the terms of these agreements, the Company has received licenses to research tools, know-how and technology claimed, in certain patents or patent applications. The Company is required to pay fees, milestones and/or royalties on future sales of products employing the technology or falling under claims of a patent, and some of the agreements require minimum royalty payments. Some of the agreements also require the Company to pay expenses arising from the prosecution and maintenance of the patents covering the inlicensed technology. The Company continually reassesses the value of the license agreements and cancels them when research efforts are discontinued on these programs. If all inlicensed and research candidates are successfully developed, the Company may be required to pay milestone payments of approximately $1 million over the lives of these agreements, in addition to royalties on sales of the affected products at rates ranging up to 5%. Due to the uncertainties of the development process, the timing and probability of the milestone and royalty payments cannot be accurately estimated.
	Litigation. From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations.

SHAREBASED_COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
SHARE-BASED COMPENSATION	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
SHARE-BASED COMPENSATION	'
	NOTE 8. SHARE-BASED COMPENSATION
	Share-Based Compensation Plans. In May 2011, the Company adopted the Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan (the 2011 Plan) pursuant to which 7.0 million shares of Company common stock were reserved for future issuance. The 2011 Plan is the successor to the Company’s 2003 Incentive Stock Plan, 2001 Stock Option Plan, 1997 Incentive Stock Plan, 1996 Director Stock Option Plan and 1992 Incentive Stock Plan (together, the Prior Plans). Although the Company no longer grants equity awards under the Prior Plans, all outstanding stock awards granted under the Prior Plans will continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the Prior Plans, as applicable.
	The 2011 Plan provides for the grant of stock options that qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (the Code), nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of equity compensation, as well as performance cash awards.
	Since 1992, the Company has authorized approximately 22.2 million shares of common stock for issuance pursuant to the Prior Plans, several Employment Commencement Nonstatutory Stock Option Agreements and the 2011 Plan (collectively, the Option Plans). The Option Plans provide for the grant of stock options, restricted stock awards, restricted stock unit awards, and stock bonuses to officers, directors, employees, and consultants of the Company. Currently, all new grants of stock options are made from the 2011 Plan or through Employment Commencement Nonstatutory Stock Option Agreements. As of December 31, 2013, of the 22.2 million shares originally reserved for issuance under the Option Plans, 4.2 million of these shares were originally reserved for issuance pursuant to the terms of the Prior Plans and would currently be available for issuance but for the Company’s determination not to make further grants under these plans; 8.9 million were issued upon exercise of stock options or pursuant to restricted stock or stock bonus awards; 6.2 million were subject to outstanding options and restricted stock units; and 2.9 million remained available for future grant under the 2011 Plan. Share awards made under the 2011 Plan that are subsequently cancelled due to forfeiture or expiration are returned to the share pool available for future grants.

	The Company issues new shares upon the exercise of stock options, the issuance of stock bonus awards and vesting of restricted stock units, and has 9.1 million shares of common stock reserved for such issuance as of December 31, 2013.
	Vesting Provisions of Share-Based Compensation. Stock options granted under the Option Plans have terms from seven to ten years from the date of grant, and generally vest over a three to four-year period. Restricted stock units granted under the Option Plans generally have vesting periods of four years. The maximum contractual term for all options granted from the 2011 Plan is ten years.
	Share-Based Compensation. The compensation cost that has been included in the statement of comprehensive (loss) income for all share-based compensation arrangements is as follows (in thousands):


		Years Ended December 31,
		2013			2012			2011
	General and administrative expense	$	3,516		$	2,746		$	1,760
	Research and development expense		3,303			2,733			1,158

	Share-based compensation expense	$	6,819		$	5,479		$	2,918

	Authoritative guidance requires that cash flows resulting from tax deductions in excess of the cumulative compensation cost recognized for options exercised be classified as cash inflows provided by financing activities and cash outflows used in operating activities. Due to the Company’s net tax loss position, no tax benefits have been recognized in the consolidated statements of cash flows.
	Stock Options. The exercise price of all options granted during the years ended December 31, 2013, 2012 and 2011 was equal to the closing price of the Company’s common stock on the date of grant. The estimated fair value of each option award granted was determined on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions for option grants during the three years ended December 31, 2013:


		Years Ended December 31,
		2013			2012			2011
	Risk-free interest rate		1.4	%		1.3	%		1.4	%
	Expected volatility of common stock		76	%		79	%		82	%
	Dividend yield		0	%		0	%		0	%
	Expected option term		7.3 years			6.8 years			6.2 years
	The Company estimates the fair value of stock options using a Black-Scholes option-pricing model on the date of grant. The fair value of equity instruments that are ultimately expected to vest, net of estimated forfeitures, are recognized and amortized on a straight-line basis over the requisite service period. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, expected term and interest rates. The expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options. The expected option term is estimated based on historical experience as well as the status of the employee. For example, Directors and Officers have a longer expected option term than all other employees. Additionally, recent grants of stock options have a contractual life of ten years, versus seven years for older option grants, and the vesting period for recent option grants has been extended to four years, which together have resulted in an increase in the expected option term. The risk-free rate for periods within the contractual life of the option is based upon observed interest rates appropriate for the expected term of the Company’s employee stock options. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.
	Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Pre-vesting forfeitures for awards with monthly vesting terms were estimated to be 0% in 2013 based on historical experience. Pre-vesting forfeitures for awards with annual vesting terms were also estimated at 0% in 2013 based on historical employee turnover experience. The effect of past restructurings has been excluded from the historical review of employee turnover. The effect of pre-vesting forfeitures for awards has historically been negligible on the Company’s recorded expense. The Company’s determination of fair value is affected by the Company’s stock price as well as a number of assumptions that require judgment. The weighted-average fair values of options granted during the years ended December 31, 2013, 2012 and 2011, estimated as of the grant date using the Black-Scholes option valuation model, were $6.55, $6.05 and $4.14, respectively.
	A summary of the status of the Company’s stock options as of December 31, 2013, 2012 and 2011 and of changes in options outstanding under the plans during the three years ended December 31, 2013 is as follows (in thousands, except for weighted average exercise price data):


		2013						2012					2011
		Options			Weighted			Options			Weighted		Options			Weighted
					Average						Average					Average
					Exercise Price						Exercise Price					Exercise Price
	Outstanding at January 1		6,166		$	7.62			5,315		$	8.82		4,047		$	11.22
	Granted/amended		771			9.24			1,446			8.5		1,605			5.9
	Exercised		(904	)		5.96			(209	)		3.49		(94	)		3.05
	Canceled		(180	)		25.68			(386	)		29.66		(243	)		31.73

	Outstanding at December 31		5,853		$	7.54			6,166		$	7.62		5,315		$	8.82

	Options outstanding at December 31, 2013 have a weighted average remaining contractual term of 5.8 years.
	For the year ended December 31, 2013, share-based compensation expense related to stock options was $6.0 million. As of December 31, 2013, there was approximately $8.8 million of unamortized compensation cost related to stock options, which is expected to be recognized over a weighted average vesting period of approximately 2.1 years. As of December 31, 2013, there were approximately 4.3 million options exercisable with a weighted average exercise price of $7.30 and a weighted-average remaining contractual term of 4.9 years. The total intrinsic value, which is the amount by which the exercise price was exceeded by the sale price of the Company’s common stock on the date of sale, of stock option exercises during the years ended December 31, 2013, 2012, and 2011 was $6.0 million, $943,000 and $423,000, respectively. As of December 31, 2013, the total intrinsic value of options outstanding and exercisable was $15.6 million. Cash received from stock option exercises for the years ended December 31, 2013, 2012 and 2011 was $5.3 million, $731,000 and $286,000, respectively.
	On January 16, 2014 the Company granted its employees approximately 0.8 million options that vest monthly over a four year period with a strike price of $19.59.
	Restricted Stock Units. Certain employees receive restricted stock units under the 2011 Plan. The fair value of restricted stock units is based on the closing sale price of the Company’s common stock on the date of issuance. The total number of restricted stock awards expected to vest is adjusted by estimated forfeiture rates, which has been based on historical experience of equity awards and historical employee turnover experience. The effect of pre-vesting forfeitures for awards has historically been negligible on the Company’s recorded expense and was estimated at 0% in 2013. The effect of past restructurings has been excluded from the historical review of employee turnover. For the year ended December 31, 2013, 2012 and 2011, share-based compensation expense related to restricted stock units was $0.8 million, $0, and $0.5 million, respectively. As of December 31, 2013, there was approximately $2.4 million of unamortized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average vesting period of approximately 3.0 years.

	The total intrinsic value of restricted stock units converted into common shares during the years ended December 31, 2013, 2012 and 2011 was $0, $0.4 million, and $1.9 million, respectively. The restricted stock units, at the election of eligible employees, may be subject to deferred delivery arrangement. The total intrinsic value of restricted stock units outstanding at December 31, 2013 was $3.5 million based on the Company’s closing stock price on that date.
	A summary of the status of the Company’s restricted stock units as of December 31, 2013, 2012 and 2011 and of changes in restricted stock units outstanding under the plans for the three years ended December 31, 2013 is as follows (in thousands, except for weighted average grant date fair value per unit):


		2013						2012					2011
		Number of			Weighted Average			Number of			Weighted Average		Number of			Weighted Average
		Units			Grant Date Fair			Units			Grant Date Fair		Units			Grant Date Fair
					Value per Unit						Value per Unit					Value per Unit
	Restricted stock units outstanding at January 1		—		$	—			50		$	5.88		287		$	5.08
	Restricted stock units granted		379			8.65			—			—		50			5.88
	Restricted stock units cancelled		(6	)		8.65			—			—		—			—
	Restricted stock units converted into common shares		—			—			(50	)		5.88		(287	)		5.08

	Restricted stock units outstanding at December 31		373		$	8.65			—		$	—		50		$	5.88

On January 16, 2014 the Company granted its employees approximately 0.4 million restricted stock units that vest annually over a four year period, and approximately 0.5 million restricted stock units that are subject to performance based vesting.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
STOCKHOLDERS' EQUITY	Dec. 31, 2013
Equity [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 9. STOCKHOLDERS’ EQUITY
	Equity Financing
	In January 2012, the Company completed a public offering of common stock in which the Company sold 10.9 million shares of its common stock at an offering price of $8.10 per share. The shares were sold pursuant to a shelf registration statement previously on file with the SEC. The net proceeds generated from this transaction, after underwriting discounts and commissions and offering costs, were approximately $83.0 million.
	Shelf Registration Statement
	In December 2012, the SEC declared effective a shelf registration statement filed by the Company in November 2012. The shelf registration statement allows the Company to issue shares of its common stock from time to time for an aggregate initial offering price of up to $150 million. The specific terms of future offerings, if any, under the shelf registration statement would be established at the time of such offerings.

INCOME_TAXES

INCOME TAXES	12 Months Ended
INCOME TAXES	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 10. INCOME TAXES
	On January 1, 2007, the Company adopted the provisions of the FASB’s authoritative accounting guidance, which, among other things, related to uncertain tax positions. Under the accounting guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
	There were no unrecognized tax benefits as of the date of adoption. As a result of the implementation of the guidance, the Company did not recognize an increase in the liability for unrecognized tax benefits and did not have any unrecognized tax benefits included in the balance sheet that would, if recognized, affect the effective tax rate. The adoption of the guidance did not impact the Company’s financial condition, results of operations or cash flows.
	The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s consolidated balance sheets at December 31, 2013 or December 31, 2012, and has not recognized interest and/or penalties in the statement of comprehensive (loss) income for the year ended December 31, 2013.
	The Company is subject to taxation in the United States and various state jurisdictions. The Company’s tax years for 1995 and forward are subject to examination by the United States and California tax authorities due to the carry forward of unutilized net operating losses and R&D credits.
	At December 31, 2013, the Company had deferred tax assets of $341.7 million. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these assets, a full valuation has been established to offset the net deferred tax asset. Additionally, the future utilization of the Company’s net operating loss and research and development credit carry forwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that could occur in the future. The Company has determined that no ownership changes have occurred through December 31, 2013.
	At December 31, 2013, the Company had Federal and California income tax net operating loss carry forwards of approximately $624.9 million and $612.3 million, respectively. The Federal and California tax loss carry forwards will begin to expire in 2021 and 2015, respectively, unless previously utilized. In addition, the Company has Federal and California R&D tax credit carry forwards of $32.6 million and $22.7 million, respectively. The Federal research and development tax credit carry forwards begin expiring in 2018 and will continue to expire unless utilized. The California research and development tax credit carryforwards carry forward indefinitely. The Company also has Federal Alternative Minimum Tax credit carryforwards of approximately $241,000, which will carry forward indefinitely. At December 31, 2013, approximately $18.2 million of the net operating loss carry forwards relate to stock option exercises, which will result in an increase to additional paid-in capital and a decrease in income taxes payable at the time when the tax loss carryforwards are utilized.

	Significant components of the Company’s deferred tax assets as of December 31, 2013 and 2012 are listed below. A valuation allowance of $341.7 million and $321.2 million at December 31, 2013 and 2012, respectively, has been recognized to offset the deferred tax assets as realization of such assets is uncertain. Amounts are shown as of December 31 as of each respective year (in thousands):


		2013			2012
	Deferred tax assets:
	Net operating losses	$	246,500		$	236,500
	Research and development credits		27,700			25,600
	Capitalized research and development		34,500			21,000
	Share-based compensation expense		5,200			4,900
	Deferred revenue		800			2,000
	Deferred gain on sales leaseback		8,500			9,800
	Intangibles		13,200			15,800
	Cease-use expense		1,300			1,500
	Fixed assets		300			200
	Other		3,700			3,900

	Total deferred tax assets		341,700			321,200
	Valuation allowance		(341,700	)		(321,200	)

	Net deferred tax assets	$	—		$	—

	The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2013, 2012 and 2011, due to the following (in thousands):


		2013			2012			2011
	Federal income taxes at 35%	$	(16,131	)	$	1,759		$	13,150
	State income tax, net of Federal benefit		(2,611	)		406			2,230
	Tax effect on non-deductible expenses		7			9			43
	Share-based compensation expense		215			1,154			385
	Expired tax attributes		151			327			159
	Research credits		(3,458	)		(428	)		(3,395	)
	(Re-established)/removal of net operating losses and R&D credits		—			—			(278,778	)
	Change in valuation allowance		20,504			(4,061	)		248,803
	Uncertain tax positions		1,283			876			17,432
	Other		40			(42	)		(29	)

		$	—		$	—		$	—

	The following table summarizes the activity related to our unrecognized tax benefits (in thousands):


		2013			2012			2011
	Balance as of the beginning of the year	$	21,672		$	20,237		$	—
	Increases related to prior year tax positions		543			1,434			19,922
	Increases related to current year tax positions		916			165			395
	Expiration of the statute of limitations for the assessment of taxes		—			(164	)		(80	)

	Balance as of the end of the year	$	23,131		$	21,672		$	20,237

	The Company has concluded that an ownership change did not occur in the current or prior years. However, the Company, under authoritative guidance, excluded those deferred tax assets that are not more likely than not to be sustained under the technical merits of the tax position. These unrecognized tax benefits totaled $0.5 million and $0.9 million for prior year tax positions and current year tax positions, respectively, as reflected in the tabular rollforward above.

	As of December 31, 2013, the Company had $19.6 million of unrecognized tax benefits that, if recognized and realized, would effect the effective tax rate.
	In the next twelve months, the Company does not expect a significant change in their unrecognized tax benefits.

RETIREMENT_PLAN

RETIREMENT PLAN	12 Months Ended
RETIREMENT PLAN	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
RETIREMENT PLAN	'
	NOTE 11. RETIREMENT PLAN
	The Company has a 401(k) defined contribution savings plan (401(k) Plan). The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees up to 60% of base salary limited by the IRS-imposed maximum. Employer contributions were $0.3 million, $0.2 million and $0.2 million for the years ended December 31, 2013, 2012 and 2011, respectively.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 12. SUBSEQUENT EVENTS
	The Company evaluated all subsequent events that have occurred after the date of the accompanying financial statements and determined that there were no events or transactions occurring during this subsequent event reporting period which require recognition or disclosure in the Company’s financial statements, other than as disclosed below.

SELECTED_QUARTERLY_FINANCIAL_D

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	'
	NOTE 13. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
	The following is a summary of the quarterly results of the Company for the years ended December 31, 2013 and 2012 (unaudited, in thousands, except for per share data):


		Year Ended December 31,												Year Ended
		First			Second			Third			Fourth			December 31
		Quarter			Quarter			Quarter			Quarter
	2013:00:00
	Revenues	$	730		$	730		$	729		$	730		$	2,919
	Operating expenses		13,705			13,897			12,735			12,260			52,597
	Net loss		(12,075	)		(12,242	)		(11,131	)		(10,642	)		(46,090	)
	Net loss per share:
	Basic	$	(0.18	)	$	(0.18	)	$	(0.17	)	$	(0.16	)	$	(0.69	)
	Diluted	$	(0.18	)	$	(0.18	)	$	(0.17	)	$	(0.16	)	$	(0.69	)
	Shares used in the calculation of net loss per share:
	Basic		66,600			66,799			67,199			67,346			66,989
	Diluted		66,600			66,799			67,199			67,346			66,989
	2012:00:00
	Revenues	$	11,267		$	10,569		$	9,357		$	21,947		$	53,140
	Operating expenses		13,059			11,949			13,319			13,365			51,692
	Net income (loss)		(886	)		(501	)		(3,078	)		9,490			5,025
	Net income (loss) per share:
	Basic	$	(0.01	)	$	(0.01	)	$	(0.05	)	$	0.14		$	0.08
	Diluted	$	(0.01	)	$	(0.01	)	$	(0.05	)	$	0.14		$	0.08
	Shares used in the calculation of net income (loss) per share:
	Basic		63,409			66,309			66,342			66,406			65,619
	Diluted		63,409			66,309			66,342			67,720			66,946

ORGANIZATION_AND_SUMMARY_OF_SI1

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Cash Equivalents

Short-Term Investments Available-for-Sale

Concentration of Credit Risk

Collaboration Agreements

Collaboration Agreements. During the years ended December 31, 2013, 2012, and 2011, collaborative research and development agreements accounted for all of the Company’s revenue.

Property and Equipment

Industry Segment and Geographic Information

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

Research and Development Expenses

Share-Based Compensation

Investment Income, net

Years Ended December 31,

2013

2012

2011

Interest income

400

489

435

Realized gains/(losses), net

—

(17

)

Total

402

489

418

Net (Loss) Income Per Share

Impact of Recently Issued Accounting Standards

Revenue Recognition Policy

Revenue Recognition Policy. Revenues under collaborative agreements and grants are recognized as research costs are incurred over the period specified in the related agreement or as the services are performed. These agreements are on a best-efforts basis, do not require scientific achievement as a performance obligation and provide for payment to be made when costs are incurred or the services are performed. All fees are nonrefundable to the collaborators. Prior to the revised multiple element guidance adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Estimating the duration of the development period includes continual assessment of development stages and regulatory requirements. If and when the Company enters into a new collaboration agreement or materially modifies an existing collaboration agreement, the Company will be required to apply the new multiple element guidance. Milestone payments are recognized as revenue upon achievement of pre-defined scientific events, which require substantive effort, and for which achievement of the milestone was not readily assured at the inception of the agreement.

ORGANIZATION_AND_SUMMARY_OF_SI2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Components of Investment Income	'
	The following table presents certain information related to the components of investment income (in thousands):


		Years Ended December 31,
		2013		2012		2011
	Interest income		400		489		435
	Realized gains/(losses), net		2		—		(17	)

	Total	$	402	$	489	$	418

REVENUE_RECOGNITION_AND_SIGNIF1

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Boehringer Ingelheim International GmbH	'
Revenues Recognized under Collaboration Agreement	'
	During the years ended December 31, 2012 and 2011, revenues recognized under the collaboration agreement with Boehringer Ingelheim were as follows (in millions):


		Year Ended
		December 31,
		2012		2011
	Amortization of up-front license fees	$	2.2	$	5
	Sponsored research and development		1		1.3

	Revenues recognized under the Boehringer Ingelheim collaboration agreement	$	3.2	$	6.3

AbbVie	'
Revenues Recognized under Collaboration Agreement	'
	During the years ended December 31, 2012 and 2011, revenues recognized under the collaboration agreement with AbbVie were as follows (in millions):


		Year Ended
		December 31,
		2012		2011
	Milestones and amortization of up-front license fees	$	29.1	$	59
	Sponsored research and development		17.8		9.1

	Revenues recognized under the AbbVie collaboration agreement	$	46.9	$	68.1

INVESTMENTS_Tables

INVESTMENTS (Tables)	12 Months Ended
INVESTMENTS (Tables)	Dec. 31, 2013
Investments Schedule [Abstract]	'
Investments	'
	Investments at December 31, 2013 and 2012 consisted of the following (in thousands):


			Years Ended
			December 31,
			2013		2012
	Certificates of deposit		$	11,012	$	12,434
	Commercial paper			4,997		19,695
	Corporate debt securities			77,441		77,610
	Securities of government-sponsored entities			7,500		—

	Total investments		$	100,950	$	109,739

Summary of Investments Classified as Available-For-Sale Securities	'
	The following is a summary of investments classified as available-for-sale securities (in thousands):


			Contractual		Amortized			Gross		Gross			Aggregate
			Maturity		Cost			Unrealized		Unrealized			Estimated
			(in years)					Gains(1)		Losses(1)			Fair
													Value
	December 31, 2013:
	Classified as current assets:
	Certificates of deposit			Less than 1	$	11,018		$	1	$	(7	)	$	11,012
	Commercial paper			Less than 1		4,997			—		—			4,997
	Corporate debt securities			Less than 1		77,430			19		(8	)		77,441
	Securities of government-sponsored entities			Less than 1		7,500			—		—			7,500

	Total short-term available-for-sale securities				$	100,945		$	20	$	(15	)	$	100,950

	December 31, 2012:
	Classified as current assets:
	Certificates of deposit			Less than 1	$	11,960		$	—	$	(6	)	$	11,954
	Commercial paper			Less than 1		19,713			—		(18	)		19,695
	Corporate debt securities			Less than 1		77,588			33		(11	)		77,610

	Total short-term available-for-sale securities				$	109,261		$	33	$	(35	)	$	109,259

	Classified as non-current assets:
	Certificates of deposit			1 to 2	$	480		$	—	$	—		$	480

	Total long-term available-for-sale securities				$	480		$	—	$	—		$	480


	-1	Unrealized gains and losses are included in other comprehensive income.
Sales and Maturities of Available-For-Sale Investments	'
	The following table presents certain information related to sales and maturities of available-for-sale investments (in thousands):


			Year Ended December 31,
			2013		2012			2011
	Proceeds from sales/maturities of available-for-sale securities		$	151,283	$	132,520		$	134,259
	Gross realized gains on sales of available-for-sale securities			2		—			—
	Gross realized losses on sales of available-for-sale securities			—		—			17
	Gains reclassified out of accumulated other comprehensive (loss) income into earnings			—		—			—
Available-For-Sale Investments in Unrealized Loss Position	'
	The following table presents information about available-for-sale investments in an unrealized loss position (in thousands):


			Less Than 12 Months					12 Months or Greater					Total
			Estimated		Unrealized			Estimated		Unrealized			Estimated		Unrealized
			Fair Value		Losses			Fair Value		Losses			Fair Value		Losses
	December 31, 2013:
	Certificates of deposit		$	9,802	$	(7	)	$	—	$	—		$	9,802	$	(7	)
	Corporate debt securities			29,919		(8	)		—		—			29,919		(8	)

	Total		$	39,721	$	(15	)	$	—	$	—		$	39,721	$	(15	)

	December 31, 2012:
	Certificates of deposit		$	10,273	$	(6	)	$	—	$	—		$	10,273	$	(6	)
	Commercial paper			19,695		(18	)		—		—			19,695		(18	)
	Corporate debt securities			37,524		(11	)		—		—			37,524		(11	)

	Total		$	67,492	$	(35	)	$	—	$	—		$	67,492	$	(35	)

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Assets Measured at Fair Value on Recurring Basis	'
	The Company’s assets which are measured at fair value on a recurring basis as of December 31, 2013 and 2012 were determined using the inputs described above (in millions):


					Fair Value Measurements Using
		Carrying			Quoted Prices in			Significant Other			Significant
		Value			Active Markets for			Observable			Unobservable Inputs
					Identical Assets			Inputs			(Level 3)
					(Level 1)			(Level 2)
	December 31, 2013:
	Classified as current assets:
	Cash and money market funds	$	34.9		$	34.9		$	—		$	—
	Certificates of deposit		11			11			—			—
	Commercial paper		5			—			5			—
	Securities of government-sponsored entities		7.5			—			7.5			—
	Corporate debt securities		87.4			—			87.4			—

	Subtotal		145.8			45.9			99.9			—
	Classified as long-term assets:
	Certificates of deposit		4.4			4.4			—			—

	Total		150.2			50.3			99.9			—
	Less cash, cash equivalents and restricted cash		(49.2	)		(39.3	)		(9.9	)		—

	Total investments	$	101		$	11		$	90		$	—

	December 31, 2012:
	Classified as current assets:
	Cash and money market funds	$	53.2		$	53.2		$	—		$	—
	Certificates of deposit		11.9			11.9			—			—
	Commercial paper		25.7			—			25.7			—
	Corporate debt securities		82.2			—			82.2			—

	Subtotal		173			65.1			107.9			—
	Classified as long-term assets:
	Certificates of deposit		4.8			4.8			—			—

	Total		177.8			69.9			107.9			—
	Less cash, cash equivalents and restricted cash		(68.1	)		(57.5	)		(10.6	)		—

	Total investments	$	109.7		$	12.4		$	97.3		$	—

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
PROPERTY AND EQUIPMENT (Tables)	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	Property and equipment, net, at December 31, 2013 and 2012 consisted of the following (in thousands):


		2013			2012
	Tenant improvements		1,195			1,195
	Furniture and fixtures		819			819
	Equipment		28,089			34,209

			30,103			36,223
	Less accumulated depreciation		(28,332	)		(34,323	)

	Property and equipment, net	$	1,771		$	1,900

ACCRUED_LIABILITIES_Tables

ACCRUED LIABILITIES (Tables)	12 Months Ended
ACCRUED LIABILITIES (Tables)	Dec. 31, 2013
Payables And Accruals [Abstract]	'
Accrued Liabilities	'
	Accrued liabilities at December 31, 2013 and 2012 consisted of the following (in thousands):


		2013		2012
	Accrued employee related costs	$	3,403	$	3,811
	Accrued development costs		1,387		1,231
	Other accrued liabilities		3,165		3,052

		$	7,955	$	8,094

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Changes to Accrued Cease-Use Liability	'
	The following table sets forth changes to the accrued cease-use liability during 2013 and 2012 (in thousands):


			Years Ended
			December 31,
			2013			2012
	Beginning balance		$	3,686		$	2,592
	Impact of Sublease cease-use charges(1)			—			1,360
	Change in estimate			—			(3	)
	Payments			(590	)		(263	)

	Ending balance		$	3,096		$	3,686


	-1	Total sublease cease-use expense was offset by a related adjustment to deferred rent of approximately $265,000 during 2012.
Estimated Future Annual Minimum Lease Payments	'
	As of December 31, 2013, the total estimated future annual minimum lease payments under the Company’s non-cancelable building lease for the years ending after December 31, 2013 are as follows (in thousands):


			Payment Amount
	2014		$	7,169
	2015			7,385
	2016			7,606
	2017			7,834
	2018			8,070
	Thereafter			8,311

	Total future minimum lease payments		$	46,375

SHAREBASED_COMPENSATION_Tables

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
SHARE-BASED COMPENSATION (Tables)	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Compensation Expenses Related to Share Based Compensation	'
	The compensation cost that has been included in the statement of comprehensive (loss) income for all share-based compensation arrangements is as follows (in thousands):


		Years Ended December 31,
		2013			2012			2011
	General and administrative expense	$	3,516		$	2,746		$	1,760
	Research and development expense		3,303			2,733			1,158

	Share-based compensation expense	$	6,819		$	5,479		$	2,918

Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model	'
	The estimated fair value of each option award granted was determined on the date of grant using the Black-Scholes option-pricing valuation model with the following weighted-average assumptions for option grants during the three years ended December 31, 2013:


		Years Ended December 31,
		2013			2012			2011
	Risk-free interest rate		1.4	%		1.3	%		1.4	%
	Expected volatility of common stock		76	%		79	%		82	%
	Dividend yield		0	%		0	%		0	%
	Expected option term		7.3 years			6.8 years			6.2 years
Summary and Changes in Stock Options Outstanding	'
	A summary of the status of the Company’s stock options as of December 31, 2013, 2012 and 2011 and of changes in options outstanding under the plans during the three years ended December 31, 2013 is as follows (in thousands, except for weighted average exercise price data):


		2013						2012					2011
		Options			Weighted			Options			Weighted		Options			Weighted
					Average						Average					Average
					Exercise Price						Exercise Price					Exercise Price
	Outstanding at January 1		6,166		$	7.62			5,315		$	8.82		4,047		$	11.22
	Granted/amended		771			9.24			1,446			8.5		1,605			5.9
	Exercised		(904	)		5.96			(209	)		3.49		(94	)		3.05
	Canceled		(180	)		25.68			(386	)		29.66		(243	)		31.73

	Outstanding at December 31		5,853		$	7.54			6,166		$	7.62		5,315		$	8.82

Summary and Changes in Restricted Stock Units Outstanding	'
	A summary of the status of the Company’s restricted stock units as of December 31, 2013, 2012 and 2011 and of changes in restricted stock units outstanding under the plans for the three years ended December 31, 2013 is as follows (in thousands, except for weighted average grant date fair value per unit):


		2013						2012					2011
		Number of			Weighted Average			Number of			Weighted Average		Number of			Weighted Average
		Units			Grant Date Fair			Units			Grant Date Fair		Units			Grant Date Fair
					Value per Unit						Value per Unit					Value per Unit
	Restricted stock units outstanding at January 1		—		$	—			50		$	5.88		287		$	5.08
	Restricted stock units granted		379			8.65			—			—		50			5.88
	Restricted stock units cancelled		(6	)		8.65			—			—		—			—
	Restricted stock units converted into common shares		—			—			(50	)		5.88		(287	)		5.08

	Restricted stock units outstanding at December 31		373		$	8.65			—		$	—		50		$	5.88

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
INCOME TAXES (Tables)	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Components of Deferred Tax Assets	'
	Amounts are shown as of December 31 as of each respective year (in thousands):


		2013			2012
	Deferred tax assets:
	Net operating losses	$	246,500		$	236,500
	Research and development credits		27,700			25,600
	Capitalized research and development		34,500			21,000
	Share-based compensation expense		5,200			4,900
	Deferred revenue		800			2,000
	Deferred gain on sales leaseback		8,500			9,800
	Intangibles		13,200			15,800
	Cease-use expense		1,300			1,500
	Fixed assets		300			200
	Other		3,700			3,900

	Total deferred tax assets		341,700			321,200
	Valuation allowance		(341,700	)		(321,200	)

	Net deferred tax assets	$	—		$	—

Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate	'
	The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2013, 2012 and 2011, due to the following (in thousands):


		2013			2012			2011
	Federal income taxes at 35%	$	(16,131	)	$	1,759		$	13,150
	State income tax, net of Federal benefit		(2,611	)		406			2,230
	Tax effect on non-deductible expenses		7			9			43
	Share-based compensation expense		215			1,154			385
	Expired tax attributes		151			327			159
	Research credits		(3,458	)		(428	)		(3,395	)
	(Re-established)/removal of net operating losses and R&D credits		—			—			(278,778	)
	Change in valuation allowance		20,504			(4,061	)		248,803
	Uncertain tax positions		1,283			876			17,432
	Other		40			(42	)		(29	)

Activity Related to Unrecognized Tax Benefits	'
	The following table summarizes the activity related to our unrecognized tax benefits (in thousands):


		2013			2012			2011
	Balance as of the beginning of the year	$	21,672		$	20,237		$	—
	Increases related to prior year tax positions		543			1,434			19,922
	Increases related to current year tax positions		916			165			395
	Expiration of the statute of limitations for the assessment of taxes		—			(164	)		(80	)

	Balance as of the end of the year	$	23,131		$	21,672		$	20,237

SELECTED_QUARTERLY_FINANCIAL_D1

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	12 Months Ended
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Quarterly Results of Operations	'
	The following is a summary of the quarterly results of the Company for the years ended December 31, 2013 and 2012 (unaudited, in thousands, except for per share data):


		Year Ended December 31,												Year Ended
		First			Second			Third			Fourth			December 31
		Quarter			Quarter			Quarter			Quarter
	2013:00:00
	Revenues	$	730		$	730		$	729		$	730		$	2,919
	Operating expenses		13,705			13,897			12,735			12,260			52,597
	Net loss		(12,075	)		(12,242	)		(11,131	)		(10,642	)		(46,090	)
	Net loss per share:
	Basic	$	(0.18	)	$	(0.18	)	$	(0.17	)	$	(0.16	)	$	(0.69	)
	Diluted	$	(0.18	)	$	(0.18	)	$	(0.17	)	$	(0.16	)	$	(0.69	)
	Shares used in the calculation of net loss per share:
	Basic		66,600			66,799			67,199			67,346			66,989
	Diluted		66,600			66,799			67,199			67,346			66,989
	2012:00:00
	Revenues	$	11,267		$	10,569		$	9,357		$	21,947		$	53,140
	Operating expenses		13,059			11,949			13,319			13,365			51,692
	Net income (loss)		(886	)		(501	)		(3,078	)		9,490			5,025
	Net income (loss) per share:
	Basic	$	(0.01	)	$	(0.01	)	$	(0.05	)	$	0.14		$	0.08
	Diluted	$	(0.01	)	$	(0.01	)	$	(0.05	)	$	0.14		$	0.08
	Shares used in the calculation of net income (loss) per share:
	Basic		63,409			66,309			66,342			66,406			65,619
	Diluted		63,409			66,309			66,342			67,720			66,946

Recovered_Sheet1

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Organization And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Additional dilutive potential common shares	'	'	'	'	'	'	'	'	'	1,300,000	1,200,000
Diluted common shares outstanding	67,346,000	67,199,000	66,799,000	66,600,000	67,720,000	66,342,000	66,309,000	63,409,000	66,989,000	66,946,000	56,347,000
Anti-dilutive common stock share not included in computation of diluted earnings per share	'	'	'	'	'	'	'	'	300,000	2,200,000	1,300,000
Entity First Incorporation	'	'	'	'	'	'	'	'	'	'	'
Organization And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Date of incorporation	'	'	'	'	'	'	'	'	'1992	'	'
Place of incorporation	'	'	'	'	'	'	'	'	'California	'	'
Entity Second Incorporation	'	'	'	'	'	'	'	'	'	'	'
Organization And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Date of incorporation	'	'	'	'	'	'	'	'	'1996	'	'
Place of incorporation	'	'	'	'	'	'	'	'	'Delaware	'	'
Minimum	'	'	'	'	'	'	'	'	'	'	'
Organization And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Requisite service period of award	'	'	'	'	'	'	'	'	'3 years	'	'
Maximum	'	'	'	'	'	'	'	'	'	'	'
Organization And Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Requisite service period of award	'	'	'	'	'	'	'	'	'4 years	'	'

Components_of_Investment_Incom

Components of Investment Income (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'
Interest income	$400	$489	$435
Realized gains/(losses), net	2	'	-17
Total	$402	$489	$418

Recovered_Sheet2

Revenue Recognition and Significant Collaborative Research and Development Agreements - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2007

Jun. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2010

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2010

Dainippon Sumitomo Pharma Co Ltd

AbbVie

GlaxoSmithKline

Boehringer Ingelheim International GmbH

Development and regulatory event based payments

Commercial event based payments

Uterine Fibroids

Endometriosis

Collaboration

Preclinical milestone payments

Clinical development and commercial event based payments

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Collaborative agreement upfront payment received

$75,000,000

$10,000,000

Collaborative agreement maximum additional payment to receive

115,000,000

480,000,000

50,000,000

3,000,000

223,000,000

Milestone revenue

30,000,000

10,000,000

20,000,000

Collaborative arrangement right description

'The Company received funding for certain internal collaboration expenses which included reimbursement from AbbVie for internal and external expenses related to the GnRH Compounds through the end of 2012. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.

Patent rights period

'Ten years or the life of the related patent rights

Collaboration termination notice period

'180 days

Revenues recognized under the Boehringer Ingelheim collaboration agreement

18,897,000

10,462,000

13,100,000

3,200,000

6,300,000

Revenues recognized under the AbbVie collaboration agreement

46,900,000

68,100,000

Collaborative research period

'2 years

Deferred upfront payment recognition period

'2 years

Up-front license fees

20,000,000

Amortization of up-front license fees

2,900,000

Revenues

$730,000

$729,000

$730,000

$21,947,000

$9,357,000

$10,569,000

$11,267,000

$2,919,000

$53,140,000

$77,413,000

$100,000

Revenues_Recognized_under_Coll

Revenues Recognized under Collaboration Agreement with Abbvie Inc (Detail) (AbbVie, USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
AbbVie	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Milestones and amortization of up-front license fees	'	$29.10	$59
Sponsored research and development	'	17.8	9.1
Revenues recognized under the AbbVie collaboration agreement	$0	$46.90	$68.10

Revenues_Recognized_under_Coll1

Revenues Recognized under Collaboration Agreement with Boehringer Ingelheim (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Revenues recognized under the Boehringer Ingelheim collaboration agreement	'	$18,897,000	$10,462,000
Boehringer Ingelheim International GmbH	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Milestones and amortization of up-front license fees	'	2,200,000	5,000,000
Sponsored research and development	'	1,000,000	1,300,000
Revenues recognized under the Boehringer Ingelheim collaboration agreement	$0	$3,200,000	$6,300,000

Investments_Detail

Investments (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule of Investments [Line Items]	'	'
Investments	$100,950	$109,739
Certificates of deposit	'	'
Schedule of Investments [Line Items]	'	'
Investments	11,012	12,434
Commercial paper	'	'
Schedule of Investments [Line Items]	'	'
Investments	4,997	19,695
Corporate debt securities	'	'
Schedule of Investments [Line Items]	'	'
Investments	77,441	77,610
Securities of government-sponsored entities	'	'
Schedule of Investments [Line Items]	'	'
Investments	$7,500	'

Summary_of_Investments_Classif

Summary of Investments Classified as Available-For-Sale Securities (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'		'
Aggregate Estimated Fair Value	$100,950		$109,739
Certificates of deposit	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Aggregate Estimated Fair Value	11,012		12,434
Commercial paper	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Aggregate Estimated Fair Value	4,997		19,695
Corporate debt securities	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Aggregate Estimated Fair Value	77,441		77,610
Securities of government-sponsored entities	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Aggregate Estimated Fair Value	7,500		'
Short-term investments	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Amortized Cost	100,945		109,261
Gross Unrealized Gains	20	[1]	33	[1]
Gross Unrealized Losses	-15	[1]	-35	[1]
Aggregate Estimated Fair Value	100,950		109,259
Short-term investments \| Certificates of deposit	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available for sale securities contractual maturity	'1 year		'1 year
Amortized Cost	11,018		11,960
Gross Unrealized Gains	1	[1]	'
Gross Unrealized Losses	-7	[1]	-6	[1]
Aggregate Estimated Fair Value	11,012		11,954
Short-term investments \| Commercial paper	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available for sale securities contractual maturity	'1 year		'1 year
Amortized Cost	4,997		19,713
Gross Unrealized Losses	'		-18	[1]
Aggregate Estimated Fair Value	4,997		19,695
Short-term investments \| Corporate debt securities	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available for sale securities contractual maturity	'1 year		'1 year
Amortized Cost	77,430		77,588
Gross Unrealized Gains	19	[1]	33	[1]
Gross Unrealized Losses	-8	[1]	-11	[1]
Aggregate Estimated Fair Value	77,441		77,610
Short-term investments \| Securities of government-sponsored entities	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available for sale securities contractual maturity	'1 year		'
Amortized Cost	7,500		'
Aggregate Estimated Fair Value	7,500		'
Long-term investments	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Amortized Cost	'		480
Aggregate Estimated Fair Value	'		480
Long-term investments \| Certificates of deposit	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Amortized Cost	'		480
Aggregate Estimated Fair Value	'		$480
Long-term investments \| Certificates of deposit \| Minimum	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available for sale securities contractual maturity	'		'1 year
Long-term investments \| Certificates of deposit \| Maximum	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available for sale securities contractual maturity	'		'2 years

[1]	Unrealized gains and losses are included in other comprehensive income.

Sales_and_Maturities_of_Availa

Sales and Maturities of Available-For-Sale Investments (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Investments Schedule [Abstract]	'	'	'
Proceeds from sales/maturities of available-for-sale securities	$151,283	$132,520	$134,259
Gross realized gains on sales of available-for-sale securities	2	'	'
Gross realized losses on sales of available-for-sale securities	'	'	17
Gains reclassified out of accumulated other comprehensive (loss) income into earnings	$0	$0	$0

AvailableForSale_Investments_i

Available-For-Sale Investments in Unrealized Loss Position (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Less Than 12 Months, Estimated Fair Value	$39,721	$67,492
Less Than 12 Months, Unrealized Losses	-15	-35
12 Months or Greater, Estimated Fair Value	0	0
12 Months or Greater, Unrealized Losses	0	0
Total Estimated Fair Value	39,721	67,492
Total Unrealized Losses	-15	-35
Certificates of deposit	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Less Than 12 Months, Estimated Fair Value	9,802	10,273
Less Than 12 Months, Unrealized Losses	-7	-6
12 Months or Greater, Estimated Fair Value	0	0
12 Months or Greater, Unrealized Losses	0	0
Total Estimated Fair Value	9,802	10,273
Total Unrealized Losses	-7	-6
Commercial paper	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Less Than 12 Months, Estimated Fair Value	'	19,695
Less Than 12 Months, Unrealized Losses	'	-18
12 Months or Greater, Estimated Fair Value	'	0
12 Months or Greater, Unrealized Losses	'	0
Total Estimated Fair Value	'	19,695
Total Unrealized Losses	'	-18
Corporate debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Less Than 12 Months, Estimated Fair Value	29,919	37,524
Less Than 12 Months, Unrealized Losses	-8	-11
12 Months or Greater, Estimated Fair Value	0	0
12 Months or Greater, Unrealized Losses	0	0
Total Estimated Fair Value	29,919	37,524
Total Unrealized Losses	($8)	($11)

Assets_Measured_at_Fair_Value_

Assets Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Measurements, Recurring	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	$101	$109.70
Fair Value, Measurements, Recurring \| Investments Including Cash Equivalents And Restricted Cash	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	150.2	177.8
Fair Value, Measurements, Recurring \| Cash and Cash Equivalents	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	-49.2	-68.1
Short-term investments \| Fair Value, Measurements, Recurring	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	145.8	173
Short-term investments \| Fair Value, Measurements, Recurring \| Cash and money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	34.9	53.2
Short-term investments \| Fair Value, Measurements, Recurring \| Certificates of deposit	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	11	11.9
Short-term investments \| Fair Value, Measurements, Recurring \| Commercial paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	5	25.7
Short-term investments \| Fair Value, Measurements, Recurring \| Securities of government-sponsored entities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	7.5	'
Short-term investments \| Fair Value, Measurements, Recurring \| Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	87.4	82.2
Long-term investments \| Fair Value, Measurements, Recurring \| Certificates of deposit	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Carrying Value	4.4	4.8
Quoted Prices in Active Markets for Identical Assets (Level 1)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	11	12.4
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Investments Including Cash Equivalents And Restricted Cash	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	50.3	69.9
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Cash and Cash Equivalents	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	39.3	57.5
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	45.9	65.1
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Cash and money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	34.9	53.2
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Certificates of deposit	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	11	11.9
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Commercial paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Securities of government-sponsored entities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	'
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Short-term investments \| Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Long-term investments \| Certificates of deposit	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	4.4	4.8
Significant Other Observable Inputs (Level 2)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	90	97.3
Significant Other Observable Inputs (Level 2) \| Investments Including Cash Equivalents And Restricted Cash	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	99.9	107.9
Significant Other Observable Inputs (Level 2) \| Cash and Cash Equivalents	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	9.9	10.6
Significant Other Observable Inputs (Level 2) \| Short-term investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	99.9	107.9
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Cash and money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Certificates of deposit	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Commercial paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	5	25.7
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Securities of government-sponsored entities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	7.5	'
Significant Other Observable Inputs (Level 2) \| Short-term investments \| Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	87.4	82.2
Significant Other Observable Inputs (Level 2) \| Long-term investments \| Certificates of deposit	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Investments Including Cash Equivalents And Restricted Cash	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Cash and Cash Equivalents	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Short-term investments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Cash and money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Certificates of deposit	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Commercial paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Securities of government-sponsored entities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	'
Significant Unobservable Inputs (Level 3) \| Short-term investments \| Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) \| Long-term investments \| Certificates of deposit	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets on recurring basis	$0	$0

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$30,103	$36,223
Less accumulated depreciation	-28,332	-34,323
Property and equipment, net	1,771	1,900
Tenant improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	1,195	1,195
Furniture and fixtures	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	819	819
Equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$28,089	$34,209

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property Plant And Equipment [Abstract]	'	'	'
Depreciation	$700,000	$700,000	$700,000
Gain on disposal of capital equipment	$37,000	$32,000	$242,000

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Payables And Accruals [Abstract]	'	'
Accrued employee related costs	$3,403	$3,811
Accrued development costs	1,387	1,231
Other accrued liabilities	3,165	3,052
Accrued Liabilities, Current	$7,955	$8,094

Recovered_Sheet3

Commitments and Contingencies - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2007

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2008

Dec. 31, 2013

Sep. 30, 2012

Aug. 30, 2012

Aug. 31, 2012

Dec. 31, 2010

Sep. 30, 2011

Dec. 31, 2012

Nov. 30, 2012

Building

RenewalOptions

Minimum

Maximum

Sublease

Second Sublease

Third Sublease

sqft

Commitment And Contingencies [Line Items]

Sale of facility and associated real property

$109,000,000

Mortgage debt retired

47,700,000

Cash received net of transaction costs and debt retirement

61,000,000

Leaseback transaction lease period

'12 years

Number of building leased

Net deferred gain on real estate sale

20,900,000

39,100,000

Deferred gain recognized on real estate sale

3,100,000

3,000,000

Lease expiration year

'2019

Percentage of management fee included in the base annual rent

3.50%

Letter of credit

4,200,000

Lease extension period

'10 years

Number of times to renew the lease contract

Subleased area

17,000

16,000

3,300

14,000

Rental income from sublease agreement

600,000

100,000

500,000

Sublease agreement period

'3 years

'3 years 6 months

Lease renewal additional periods

'1 year

Cease-use expense

1,092,000

82,000

150,000

2,500,000

300,000

1,200,000

Deferred rent reversed

15,000

173,000

47,000

250,000

Rent expense

5,900,000

6,200,000

Lease period

'12 years

Lease expiration year

'2019

Cash and investment required to be maintained

50,000,000

Security deposit to be increased

5,000,000

Lease cancellation, notice period

'0 days

'180 days

Milestone payables

$1,000,000

Royalty, rate

5.00%

Changes_to_Accrued_CeaseUse_Li

Changes to Accrued Cease-Use Liability (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Commitments And Contingencies Disclosure [Abstract]	'	'
Beginning balance	$3,686	$2,592
Impact of Sublease cease-use charges	'	1,360	[1]
Change in estimate	'	-3
Payments	-590	-263
Ending balance	$3,096	$3,686

[1]	Total sublease cease-use expense was offset by a related adjustment to deferred rent of approximately $265,000 during 2012.

Changes_to_Accrued_CeaseUse_Li1

Changes to Accrued Cease-Use Liability (Parenthetical) (Detail) (Sublease, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Sublease	'
Lease Commitments And Contingencies [Line Items]	'
Deferred rent reversed	$265

Estimated_Future_Annual_Minimu

Estimated Future Annual Minimum Lease Payments (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
2014	$7,169
2015	7,385
2016	7,606
2017	7,834
2018	8,070
Thereafter	8,311
Total future minimum lease payments	$46,375

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Jan. 16, 2014

Dec. 31, 2013

Jan. 16, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 16, 2014

Dec. 31, 2013

Jan. 16, 2014

Dec. 31, 2013

31-May-11

Dec. 31, 2013

Minimum

Maximum

Stock Options

Restricted Stock Units (RSUs)

Share Based Compensation Arrangement Award

Due to Changes in the Plan

2011 Plan

Prior Plans

Stock Options, Restricted Stock Units or Stock Bonus Plans

Stock Options and Restricted Stock Unit Plans

Subsequent Event

Minimum

Maximum

Subsequent Event

Minimum

Performance Based Vesting [Member]

Scenario, Previously Reported

Subsequent Event

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Number of common stock reserved for future issuance

22,200,000

9,100,000

7,000,000

4,200,000

8,900,000

6,200,000

Number of common stock available for future grant

2,900,000

Share-based compensation, term

'3 years

'4 years

'7 years

'10 years

Restricted stock, vesting period

'4 years

'3 years

'4 years

Share-based compensation, contractual term

'10 years

'7 years

Assumption estimated forfeiture rate

0.00%

Weighted-average fair values of options granted

$6.55

$6.05

$4.14

Weighted average remaining contractual term for options outstanding

'5 years 9 months 18 days

Share-based compensation expense

$6,819,000

$5,479,000

$2,918,000

$6,000,000

$800,000

$500,000

Unrecognized compensation cost

8,800,000

2,400,000

Stock vesting period

'2 years 1 month 6 days

'3 years

Number of stock options exercisable

4,300,000

Stock options exercisable, weighted average exercise price

$7.30

Stock options exercisable, weighted-average remaining contractual term

'4 years 10 months 24 days

Stock options exercised in period intrinsic value

6,000,000

943,000

423,000

Stock options intrinsic value of options outstanding and exercisable

15,600,000

Cash received from stock option exercises

5,300,000

731,000

286,000

Stock options granted

771,000

1,446,000

1,605,000

800,000

Share-based compensation, exercise price

$9.24

$8.50

$5.90

$19.59

Total intrinsic value vested in period

400,000

1,900,000

Intrinsic value outstanding

$3,500,000

Restricted stock units granted

379,000

50,000

400,000

500,000

Compensation_Expense_Related_t

Compensation Expense Related to Share-Based Compensation (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total share-based compensation expense	$6,819	$5,479	$2,918
General and Administrative Expense	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total share-based compensation expense	3,516	2,746	1,760
Research and Development Expense	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total share-based compensation expense	$3,303	$2,733	$1,158

WeightedAverage_Assumptions_fo

Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Detail) (Stock Options)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Options	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	1.40%	1.30%	1.40%
Expected volatility of common stock	76.00%	79.00%	82.00%
Dividend yield	0.00%	0.00%	0.00%
Expected option term	'7 years 3 months 18 days	'6 years 9 months 18 days	'6 years 2 months 12 days

Summary_and_Changes_in_Stock_O

Summary and Changes in Stock Options Outstanding (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Shares	'	'	'
Outstanding, Beginning Balance	6,166	5,315	4,047
Granted/amended	771	1,446	1,605
Exercised	-904	-209	-94
Canceled	-180	-386	-243
Outstanding, Ending Balance	5,853	6,166	5,315
Outstanding, Beginning Balance	$7.62	$8.82	$11.22
Granted/amended	$9.24	$8.50	$5.90
Exercised	$5.96	$3.49	$3.05
Canceled	$25.68	$29.66	$31.73
Outstanding, Ending Balance	$7.54	$7.62	$8.82

Summary_and_Changes_in_Restric

Summary and Changes in Restricted Stock Units Outstanding (Detail) (Restricted Stock Units (RSUs), USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restricted Stock Units (RSUs)	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Restricted stock units outstanding, Beginning Balance	'	50	287
Restricted stock units granted	379	'	50
Restricted stock units cancelled	-6	'	'
Restricted stock units converted into common shares	'	-50	-287
Restricted stock units outstanding Ending Balance	373	'	50
Restricted stock units outstanding Beginning Balance	'	$5.88	$5.08
Restricted stock units granted	$8.65	'	$5.88
Restricted stock units cancelled	$8.65	'	'
Restricted stock units converted into common shares	'	$5.88	$5.08
Restricted stock units outstanding Ending Balance	$8.65	'	$5.88

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jan. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Stock [Line Items]	'	'	'	'
Common stock issued	10,900	'	'	'
Common stock, offering price	$8.10	'	'	'
Proceeds from common stock issuance	$83,000,000	$5,302,000	$83,702,000	$286,000
Shelf Registration \| Maximum	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Aggregate initial offering price of common stock	'	'	$150,000,000	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 01, 2007
Income Taxes [Line Items]	'	'	'	'
Percentage of uncertain tax positions likelihood of being sustained	50.00%	'	'	'
Unrecognized tax benefits	$23,131,000	$21,672,000	$20,237,000	$0
Accrual interest or penalties	0	0	'	'
Deferred tax assets	341,700,000	321,200,000	'	'
Research and development tax credit carry forwards	27,700,000	25,600,000	'	'
Net operating loss carry forwards related to stock option exercises	18,200,000	'	'	'
Deferred tax assets, valuation allowance	341,700,000	321,200,000	'	'
Increases related to prior year tax positions	543,000	1,434,000	19,922,000	'
Increases related to current year tax positions	916,000	165,000	395,000	'
Unrecognized tax benefits that would affect effective tax rate	19,600,000	'	'	'
Federal	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Operating loss carry forward, net	624,900,000	'	'	'
Operating loss carry forward beginning expiration year	'2021	'	'	'
Research and development tax credit carry forwards	32,600,000	'	'	'
Alternative Minimum Tax credit carry forwards	241,000	'	'	'
Federal \| R&D	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Tax credit carry forwards beginning expiration year	'2018	'	'	'
California	'	'	'	'
Income Taxes [Line Items]	'	'	'	'
Operating loss carry forward, net	612,300,000	'	'	'
Operating loss carry forward beginning expiration year	'2015	'	'	'
Research and development tax credit carry forwards	$22,700,000	'	'	'

Components_of_Deferred_Tax_Ass

Components of Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Net operating losses	$246,500	$236,500
Research and development credits	27,700	25,600
Capitalized research and development	34,500	21,000
Share-based compensation expense	5,200	4,900
Deferred revenue	800	2,000
Deferred gain on sales leaseback	8,500	9,800
Intangibles	13,200	15,800
Cease-use expense	1,300	1,500
Fixed assets	300	200
Other	3,700	3,900
Total deferred tax assets	341,700	321,200
Valuation allowance	-341,700	-321,200
Net deferred tax assets	$0	$0

Provision_for_Income_Taxes_on_

Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal income taxes at 35%	($16,131)	$1,759	$13,150
State income tax, net of Federal benefit	-2,611	406	2,230
Tax effect on non-deductible expenses	7	9	43
Share-based compensation expense	215	1,154	385
Expired tax attributes	151	327	159
Research credits	-3,458	-428	-3,395
(Re-established)/removal of net operating losses and R&D credits	'	'	-278,778
Change in valuation allowance	20,504	-4,061	248,803
Uncertain tax positions	1,283	876	17,432
Other	40	-42	-29
Income Tax Expense (Benefit), Total	$0	$0	$0

Provision_for_Income_Taxes_on_1

Provision for Income Taxes on Earnings Subject to Income Taxes Differs from Statutory Federal Rate (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Federal income taxes, rate	35.00%	35.00%	35.00%

Activity_Related_to_Unrecogniz

Activity Related to Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 01, 2007
Income Tax Disclosure [Abstract]	'	'	'	'
Unrecognized tax benefit beginning Balance	$21,672	$20,237	'	$0
Increases related to prior year tax positions	543	1,434	19,922	'
Increases related to current year tax positions	916	165	395	'
Expiration of the statute of limitations for the assessment of taxes	'	-164	-80	'
Unrecognized tax benefit ending Balance	$23,131	$21,672	$20,237	$0

Retirement_Plan_Additional_Inf

Retirement Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Compensation And Retirement Disclosure [Abstract]	'	'	'
Defined contribution plan, maximum employee contribution percentage	60.00%	'	'
Defined contribution plan, employer contribution amount	$0.30	$0.20	$0.20

Summary_of_Quarterly_Results_o

Summary of Quarterly Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$730	$729	$730	$730	$21,947	$9,357	$10,569	$11,267	$2,919	$53,140	$77,413
Operating expenses	12,260	12,735	13,897	13,705	13,365	13,319	11,949	13,059	52,597	51,692	43,491
Net income (loss)	($10,642)	($11,131)	($12,242)	($12,075)	$9,490	($3,078)	($501)	($886)	($46,090)	$5,025	$37,571
Net income (loss) per share:	'	'	'	'	'	'	'	'	'	'	'
Basic	($0.16)	($0.17)	($0.18)	($0.18)	$0.14	($0.05)	($0.01)	($0.01)	($0.69)	$0.08	$0.68
Diluted	($0.16)	($0.17)	($0.18)	($0.18)	$0.14	($0.05)	($0.01)	($0.01)	($0.69)	$0.08	$0.67
Shares used in the calculation of net income (loss) per share:	'	'	'	'	'	'	'	'	'	'	'
Basic	67,346	67,199	66,799	66,600	66,406	66,342	66,309	63,409	66,989	65,619	55,176
Diluted	67,346	67,199	66,799	66,600	67,720	66,342	66,309	63,409	66,989	66,946	56,347